Mualliflar

  • Abdullayeva Ch.A., Jo‘rayev M.I., Baxranova D.F.

##semicolon##

ишемическая болезнь сердца, сахарный ди- абет 2-го типа, эндотелиальная дисфункция, оксид азота, поли- морфизм гена NOS3.

##submission.citations##

1. Камилова УК, Атаходжаева ГА, Машарипова ДР и др. Изучение особенностей процессов ремоделирования сердца в зависимости от степени дисфункции почек. Тер вестн Узбекистана.2022;(1):24-30.

2. Akbari M et al. Polymorphisms in NOS3 and risk of vascular complications in T2DM. Diabetes Metab Syn- dr.2020;14(6):1815-21.

3. Alvim RO et al. NOS3 polymorphism and endothelial func- tion in metabolic syndrome. BMC Cardiovasc Dis.2018;18:57.

4. Chen J et al. Impact of NOS3 variants on endothelial func- tion in T2DM. J Diabetes Complications.2019;33(3):198-204.

5. De Caterina R et al. Nitric oxide signaling in cardiovascu- lar health and disease. Mol Aspects Med.2021;76:100870.

6. Del Turco S et al. Endothelial dysfunction markers in pa- tients with diabetes. Nutrients.2020;12(6):1834.

7. Ghasemi M et al. Genetic variations of NOS3 and risk of metabolic syndrome. Gene. 2017;627:354-60.

8. Kamilova UK, Abdullaeva ChA, Zakirova GA, Tagaeva DR., Masharipova D.R. Assessment of kidney dysfunction in patients with chronic heart failure. Georgian Medical News.2022;(7):1-5.

9. Li H et al. Endothelial dysfunction and nitric oxide: genet- ic insights. J Clin Med.2020;9(7):2336.

10. Lima JAC et al. Vascular function in diabetes: patho- physiological mechanisms and clinical implications. Circula-

tion.2021;143(6):557-74.

11. Mahmoudpour SH et al. Association between NOS3 poly- morphisms and cardiovascular diseases: a systematic review and meta-analysis. Sci Rep.2019;9:13668.

12. Reinders J et al. NOS3 expression and genetic variants in vascular disease. Front Genet.2020;11:595.

13. Serban C et al. Inflammation and endothelial dysfunction in diabetes. Exp Ther Med.2019;18(3):2471-6.

14. Simonsen U et al. Endothelial function in diabetes: new biomarkers. Diab Obes Metab.2022;24(1):15-24.

15. Tang S et al. Endothelial dysfunction in diabetes: the role of NO. Cardiovasc Diab. 2021;20:72.

16. Thijssen DHJ et al. Assessment of flow-mediat- ed dilation in humans. Amer J Physiol Heart Circ Physi- ol.2019;316(1):H1-H12.

17. Trabetti E. The role of eNOS gene polymorphisms in hy- pertension. J Hypertens Res.2020;6(1):34-42.

18. Tziomalos K et al. Endothelial dysfunction in insulin re- sistance and T2DM. Curr Vasc Pharmacol.2018;16(6):587-93.

19. Wang Y et al. Glu298Asp polymorphism and risk of type 2 diabetes-related complications. Diab Res Clin Pract.2017;134:78-85.

20. Zhang D et al. Genetic polymorphisms of NOS3 in diabetic complications: a review. Biomed Rep. 2021;14(3):37.

21. Zhang X et al. The impact of NOS3 gene polymorphisms on coronary artery disease risk: a meta-analysis. Int J Cardiol. 2018;252:162-9.

22. Zintzaras E et al. eNOS polymorphisms and coro- nary artery disease: updated meta-analysis. J Hum Genet. 2017;62:831-41.